Immune Design Corp (NASDAQ:IMDZ) Awarded Orphan Drug Designation

Immune Design Corp (NASDAQ:IMDZ)

Immune Design Corp (NASDAQ:IMDZ) shares fell 16% after the clinical stage company announced that the European Medicine Agency had granted its immunotherapy, G100, for non-Hodgkin’s lymphoma Orphan Drug Designation. The EMA designation is normally assigned to products targeting the treatment of rare medical conditions with prevalence of not more than 5 in 10,000 people.

The designation accords Immune Design Corp (NASDAQ:IMDZ) a string of benefits not limited to reduced fees for regulatory activities. The company also stands to enjoy protocol assistance when it comes to clinical trials. In addition, the clinical stage immunotherapy company will be granted 10 years of market exclusivity upon approval by regulators in the Union.

The company’s lead drug for the treatment of non-Hodgkin’s lymphoma has also been granted Orphan Drug Designation in the U.S by the Food and Drug Administration. Developed from Immune Design Corp (NASDAQ:IMDZ)’s GLAAS discovery platform, the candidate product is designed to activate innate and adaptive immunity in the tumor microenvironment.

IMDZ Stock Performance

Immune Design Corp (NASDAQ:IMDZ)

Immune Design Corp (NASDAQ:IMDZ) free fall in the market shows no signs of slowing down as the stock has shed more than 40% in market value since the start of the month. The stock is currently trading at levels last seen at the start of the year.

Declining investor’s sentiments on the stock follows reports that the company plans to initiate a Phase 3 study of cancer vaccine candidate CMB305 in NY-ESO-1. The timing of the study, slated for mid-2018, appears to have spooked investors. The stock has also been downgraded by analysts at Wells Fargo to a ‘Neutral’ – seen as another cause for alarm among investors.

Immune Design Pipeline

CMB305 is one of Immune Design primary candidates currently in multiple clinical trials in patients with soft tissue sarcoma. The product is being investigated as a monotherapy and in combination with Roche Holding Ltd. (ADR) (OTCMKTS:RHHBY)’s RHHBY Tecentriq.

“The trial will have progression-free survival (PFS) followed by overall survival (OS) as co-primary endpoints. If the PFS endpoint is successful, the FDA offered that it may support full approval of CMB305. Depending on the rate of events, final PFS analysis may occur as early as 24 months from the first patient dosed,” Immune Design in a statement.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $IMDZ and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Immune Pharmaceuticals Inc. (NASDAQ:IMNP) Drops 37%

Immune Pharmaceuticals Inc. (NASDAQ:IMNP)

Immune Pharmaceuticals Inc. (NASDAQ:IMNP) felt the wrath of Wall Street after announcing the pricing of an underwritten public offering from which it expects gross proceeds of $18 million. Shares of the biopharmaceutical company fell 37.42% to end Thursday’s trading session at $37.4%.

Immune Pharmaceuticals Inc. (NASDAQ:IMNP)

Investors Reaction

The sell-off came on growing concerns that the public offering could plunge the stock into more debt. Investors also reacted to concerns that the offering will result in further dilution of the stock. Thursday’s sell-off plunged the stock to multi-year lows.

The stock is currently trading in a strong downtrend after underperforming the overall industry for the better part of the year. IMNP is down by more than 70% for the year as its sentiments on Wall Street continue to turn from bad to worse.

Immune Pharmaceuticals Inc. (NASDAQ:IMNP) offering comprises of units priced at $1,000 a unit. Each unit on offer comprises of one share of Series E Convertible preferred stock and 982 warrants for the purchase of one share of the company. The Warrants are exercisable at $1.10 and expire in seven years.

Immune Pharmaceuticals Pipeline

The pricing of the public offering comes at a time when Immune Pharmaceuticals Inc. (NASDAQ:IMNP) has narrowed its focus on two promising products. The company is currently conducting Phase II clinical trial on its lead candidate drug Bertilimumab, for the treatment of patients suffering from bullous pemphigoid. The biopharmaceutical company is also investigating the drug for the treatment of ulcerative colitis.

Immune Pharmaceuticals Inc. (NASDAQ:IMNP) is fresh from reporting positive Phase 2 clinical trials for moderate to severe bullous pemphigoid clinical trials. Trial results from six patients enrolled in the trial indicate a decline in patients total activity score by 85%.

“If bertilimumab can substantially reduce or perhaps even eliminate the need for systemic corticosteroids in the treatment of bullous pemphigoid and their significant toxicity in this elderly population, it will be a major step forward in the management of what is the most common blistering disease,” said Dr. Neil Korman.

According to the Chief Executive Officer, Elliot Maza, the topline preliminary results support the company’s strategy of focusing human capital and financial resources on Bertilimumab. Immune Pharmaceuticals Inc. (NASDAQ:IMNP) is currently preparing to enroll patients in Phase 2 open-label of BP trial.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $IMNP and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: James Marion is a University of Houston student studying Business with a concentration in Finance. James has interned with several investment professionals and hopes to pursue a career as a professional stock analyst after graduation.

Alcobra Ltd (NASDAQ:ADHD) Makes Strong Move Up

Alcobra Ltd (NASDAQ:ADHD)

Israeli-based Alcobra Ltd (NASDAQ:ADHD) stock gained almost 19% after it was announced that the biotechnology company had entered into a research collaboration and worldwide license agreement with Janssen Pharmaceuticals, Inc. (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson (NYSE:JNJ). Volume exploded and was almost 100 times the daily average by the end of trading.

NASDAQ:ADHD

Deal Details

An Alcobra subsidiary, Arcturus, and Janssen will collaborate to develop and commercialize nucleic acid-based drug products for the treatment of Hepatitis B, using Arcturus’ UNA Oligomer chemistry and LUNAR™ lipid-mediated delivery platform. The agreement also includes an option to expand into other infectious and respiratory diseases. Terms of the agreement include Arcturus receiving an upfront cash payment, R&D support, and pre-clinical, development, and sales milestone payments, as well as royalty payments on any future licensed product sales. Janssen will assume responsibility for development costs and all commercialization costs associated with the program.

Joseph Payne, President and CEO of Arcturus. “Arcturus’ expertise and intellectual property in the field of RNA medicines is complemented by Janssen’s broad capabilities in clinical development, regulatory affairs, and marketing. Together we aim to bring new treatments to patients who are suffering from Hepatitis B and potentially other infectious diseases.”

ADHD Stock Performance

Shares of Alcobra Ltd (NASDAQ:ADHD) are down over 36% for the year but are up almost 40% over the past month. In January ADHD stock plummeted over 50% when it was revealed that several law firms were pursuing class-action status for lawsuits over claims that corporate officers may have violated federal securities laws.

Interestingly, Alcobra Ltd (NASDAQ:ADHD) lists cash per share at $1.55 – more than today’s closing value.

Three firms follow Alcobra Ltd (NASDAQ:ADHD). One rates ADHD shares at a “Strong Buy”. one at a “Hold”, and one at a “Sell”.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $ADHD and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Bad Day for Dextera Surgical Inc (NASDAQ:DXTR)

Dextera Surgical Inc (NASDAQ:DXTR)

Dextera Surgical Inc (NASDAQ:DXTR) gapped down to open trading this morning, then struggled through the rest of the day, and ended down almost 25%. The company released no news that would account for the large move down. The NASDAQ market started lower today as well but ended down just 0.37%. Given that DXTR stock carries a -1.17 Beta, the shares clearly were more volatile than one would expect.

Dextera Surgical Inc (NASDAQ:DXTR)

About Dextera Surgical

Redwood City, CA-based Dextera Surgical Inc (NASDAQ:DXTR) is a global medical device company that develops proprietary stapling devices for minimally invasive surgical procedures. It primarily develops and commercializes MicroCutter 5/80, a cartridge-based micro cutter device used by for thoracic, pediatric, bariatric, colorectal, and general surgeons. The company also designs, manufactures, and markets automated anastomotic systems under the Cardica brand name for use by cardiac surgeons to perform coronary bypass surgery.

DXTR Stock

The medical device company has a market capitalization under $10 million. At the end of 2016, shares of Dextera Surgical Inc (NASDAQ:DXTR) bounced off the critical $1 per share level for three weeks before shooting above $2.25. A long slide in DXTR stock value then began in February of 2017 and shares broke through the psychologically important level of $0.50 in May. Since then DXTR stock has traded in a $0.15 – $0.40 range. Then, this week, DXTR stock hit their 52-week low of $0.13. 2017 has been tough for Dextera Surgical shareholders as DXTR shares have lost over 80% since January.

The company has an uncertain future and observers of the sector believe a sale or merger may be in the best interests of the company and shareholders. Existing shareholders are on the alert for another round of dilution as the company reportedly has just $0.05 in cash per share – that is a short runway, even for a nano-cap company. However, it should be noted that the company has been able to shrink its losses each year. In 2013, the per share loss was (-$3.95). Each year since then has seen a smaller loss and, for FY2017, the loss was a smaller (-$1.72). Also benefitting shareholders is the low share price which reflects a short-sale position on the stock’s float of less than 10%. Curiously, two investment firms rate DXTR stock as a “Strong Buy” and one rates the shares a “Hold”.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $DXTR and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Imprimis Pharmaceuticals Inc (NASDAQ:IMMY) Rockets on Open!

Imprimis Pharmaceuticals Inc (NASDAQ:IMMY)

Imprimis Pharmaceuticals Inc (NASDAQ:IMMY) shares are rocketing on the back of a press release by the biotechnology company that it is making compounded Cyclosporine-based formulations available for physicians to consider prescribing as customizable, and possibly lower-cost alternative, to Restasis® for sufferers of dry-eye disease. Within 30 minutes IMMY shares jumped over 80% on a volume figure that is over 230 times its daily average.

Imprimis Pharmaceuticals Inc (NASDAQ:IMMY)

Imprimis Pharmaceuticals Inc (NASDAQ:IMMY) is an ophthalmology-focused pharmaceutical company that produces and dispenses high quality innovative medications in all 50 states. The CEO of Imprimis Pharmaceuticals Inc (NASDAQ:IMMY), Mark L. Baum, stated “While there are an estimated 30 million Americans suffering from Dry Eye Disease, only a small fraction of these patients receive therapy. Topical Cyclosporine, which is an off-patent and inexpensive drug, can cost more than $5,000 per year when it is purchased in the commercially available form of Restasis®.”

IMMY Stock Performance

Sales posted by Imprimis Pharmaceuticals Inc (NASDAQ:IMMY) have increased each year since 2014 when it reported a figure of $1.7 million. Bu 2016 sales had improved to $19.9 million. Unfortunately, that uptrend in sales has not been duplicated in earnings. IMMY shareholders have been experiencing losses for the past five years. In 2015, IMMY stock lost (-$1.66) per share. For 2016, the company posted a per share loss of (-$1.50). Also troubling Imprimis investors is the continuing, value-destroying share dilution. In 2012, 4.49 million shares were outstanding. That number grew to 12.74 by 2016.

While IMMY stock is on fire today, the shares have not been doing well. Prior to today, IMMY shares lost over 50% and are down over 66% over the past six months. But the company does not appear to be in financial peril. According to recent reports the biotechnology company has a cash per share figure of $0.21. Analysts rate the shares a “Strong Buy” and assign it a $5.00 price target.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $IMMY and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

TrovaGene Inc. (NASDAQ:TROV) PCM-075 Demonstrates Synergy

TrovaGene Inc. (NASDAQ:TROV) PCM-075 Demonstrates Synergy

TrovaGene Inc. (NASDAQ:TROV) shares gained 9.9% after the biotechnology company reported positive preclinical research, demonstrating synergy of PCM-075 in combination with Johnson & Johnson (NYSE:JNJ) drug Zytiga. Trial results indicate that when combined, the two appear to signal a previously unknown pathway.

TrovaGene Inc. (NASDAQ:TROV)

According To Trovagene Chief Scientific Officer, Mark Erlander, the unique combination could enhance the PCM-075 mechanism in arresting cells during mitosis with subsequent tumor cell death. The biotechnology company is investigating the adenosine triphosphate (ATP) competitive inhibitor for the treatment of metastatic castration-resistant prostate cancer.

“We previously completed a Phase 1 trial in metastatic solid tumor cancers, which provided a recommended Phase 2 dose and dosing schedule for PCM-075 in a combination regimen. We are working closely with key investigators to develop a Phase 2 clinical trial protocol with oral dosing of PCM-075 and abiraterone utilizing our existing solid tumor IND,” said CEO, Bill Welch.

Orphan Drug Designation

The U.S. Food and Drug Administration (FDA) has already granted an Orphan Drug Designation to PCM-075 for the treatment of acute myeloid leukemia. According to TrovaGene Inc. (NASDAQ:TROV) CEO, the designation underscores the agency desire to accelerate the development of the therapy given that AML affects nearly 20,000 people every year in the U.S.

The Orphan Drug Designation will allow TrovaGene to accelerate the development of PCM-075. The designation also allows the company up to seven years of market exclusivity upon regulatory approval. The company plans to initiate a Phase 1b/2 open-label trial to evaluate the safety and anti-leukemic activity of the candidate drug in combination with standard care.

TROV Stock Performance

TrovaGene Inc. (NASDAQ:TROV) has been a shadow of itself in the market this year as the stock is down by more than 50% as it continues to trade in a strong downtrend. Investor confidence on the tock appears to have hit all-time lows, seen by the stock struggling to rise above the $1 a share mark.

The company reported a net loss of (-$36.81) million in its most recent quarter as it continues to waver on its path to profitability. Arousing further investors’ concerns is the rate at which the company is burning cash. TrovaGene Inc. (NASDAQ:TROV) reportedly has $7.78 million in the bank compared to negative cash flows of $29.40 million.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $TROV and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Strata Skin Sciences, Inc. (NASDAQ:SSKN) Partners with MedResults Network

Strata Skin Sciences, Inc. (NASDAQ:SSKN)

Strata Skin Sciences, Inc. (NASDAQ:SSKN) fell 3.43% after announcing the signing of an agreement with MedResults Network (MRN) which they hope will greatly benefit the company’s sales efforts in the aesthetics market.

Strata Skin Sciences, Inc. (NASDAQ:SSKN)

MRN Marketing Deal

MRN is to assist Strata Skin Sciences, Inc. (NASDAQ:SSKN) on the marketing of products for various dermatologic conditions. The Group Purchasing Organization has more than 3,000 members and dermatology offices that should be of great help in enhancing sales efforts in the industry.

“STRATA’s Aesthetic products, Nordlys and STRATAPEN, are excellent products that are in growing sectors of the Aesthetic market. MRN’s mission is to offer our members best-in-class products from world-class companies,” said MRN President, Jeff Routledge.

SSKN Stock Performance

Strata Skin had initially popped to highs of $2.70 a share on the announcement of a strategic alliance, before dropping to end Wednesday’s trading session at $1.69 a share. The stock continues to trade in a downtrend, after coming under pressure on rising to $5 a share in April.

Despite the recent sell-off in the stock, HC Wainwright & Co analyst, Joseph Pantginis, remains bullish about the medical technology company prospects. The analyst has a ‘buy’ rating on the stock with a share price target of $12.

According to the analyst, a deal with MedResults which has, more than 3,000 members could serve as an important marketing platform. Pantginis expects the deal to increase the visibility of Strata’s skin products which should lead to more sales.

Debt Settlement

Separately, Strata Skin Sciences, Inc. (NASDAQ:SSKN) recently closed a transaction with holders for its 2.25% Senior Series A Secured Convertible Debentures and 4% Senior Secured Convertible Debentures, both due July 30, 2021. The holders agreed to exchange all the debentures with a principal amount of $40.7 million for 40,617 newly created Series C shares.

The transaction eliminated Strata Skin Sciences, Inc. (NASDAQ:SSKN) senior secured debt and obligation to pay $4 million of interest payments over the next four years.

“The interest savings will also provide flexibility to carry out our strategic plan for external and organic growth. [..] Furthermore, the reduction in debt will result in a simplified balance sheet. We believe this will improve our access to the capital markets and increase our financial flexibility,” said Mr. McCaney.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $SSKN and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

Fireworks Continue for Viking Therapeutics Inc (NASDAQ:VKTX)

Viking Therapeutics Inc (NASDAQ:VKTX)

Viking Therapeutics Inc (NASDAQ:VKTX) shares continued their strong upward trajectory today as the biotechnology firm’s stock rose over 25% in today’s trading to end the day at $2.60. Volume was heavy, almost ten times their normal daily average. The gains came in two waves, one right from the moment the market opened, and another buying wave began one hour before the market close.

A 2-day chart:

Viking Therapeutics Inc (NASDAQ:VKTX)

Viking Therapeutics Recent Developments

Viking Therapeutics Inc (NASDAQ:VKTX) is a clinical-stage biopharmaceutical company focused on the development of therapies for metabolic and endocrine disorders. On October 4, 2017 VKTX shares jumped almost 9% when the company announced positive top-line results from a 25-week proof-of-concept study of VK0214 in an in vivo model of X-linked adrenoleukodystrophy (X-ALD). X-ALD is a rare and often fatal metabolic disorder characterized by a breakdown in the protective barriers surrounding brain and nerve cells. X-ALD is estimated to occur in approximately 1 in 17,000 births. The results showed that 25 weeks of treatment with VK0214 led to robust effects on multiple very long chain fatty acids.

VKTX Stock

Performance for shares of Viking Therapeutics Inc (NASDAQ:VKTX) has been strong despite the lack of any sales – though that is not unusual for a clinical-stage biotechnology firm. Over the past year shares have risen over 126% and are up 134% for the past quarter. Today’s spike eclipsed the previous 52-week high of $2.44. In 2015 the company posted a per share loss of (-$3.68) but that shrank to a per share loss of (-$0.91) in 2016. However it should be noted that in 2016 the company diluted shareholder value. In 2015 there were 6.36 million shares outstanding and then in 2016 that number grew to 16.28 million.

Viking Therapeutics Inc (NASDAQ:VKTX) is covered by two analysts. Both rate VKTX shares as a “Strong Buy”.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $VKTX and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

DarioHealth Corp (NASDAQ:DRIO) App Pushes Shares Higher

DarioHealth Corp (NASDAQ:DRIO)

DarioHealth Corp (NASDAQ:DRIO), a developer of App-based diabetes management systems, shares are up over 30% with an hour left in the trading day. Volume for the nano-cap healthcare technology firm are massive. DRIO stock is listed with an average daily trading volume of less than 30,000 shares traded per day. Before the end of trading today already over six million shares have been traded.

NASDAQ:DRIO

DarioHealth Business Model

Israeli-based DarioHealth Corp (NASDAQ:DRIO) develops proprietary technologies using smart phones and other mobile devices. Its flagship product is Dario, a mobile, real-time, cloud-based, diabetes management solution based on a multi-feature software application combined with Dario Smart Meter, a pocket-sized, blood glucose monitoring device.

Today DarioHealth Corp (NASDAQ:DRIO) announced that it received the CE Mark for its Lightning®-enabled version of the acclaimed Dario™ Blood Glucose Monitoring System. The news ensures that consumers, beginning in the UK market, will be able to receive the same quality user experience with DarioHealth on the latest Apple devices, including the brand-new iPhone 8.

Erez Raphael, Chairman and CEO of DarioHealth Corp (NASDAQ:DRIO), commented, “We’ve been working tirelessly to bring forth a solution that would meet the rigorous standards required to achieve the CE Mark. We are proud that our organization worked with agility to ensure connectivity to the latest Apple devices. This significant milestone will allow us to open to a whole new market segment and reengage with former-Dario users who now have the newest Apple devices.”

DRIO Stock

DRIO stock tried to break through the $3 level back in May but without success. The shares then slid and traded in a $1.80-$2.00 range for the last several weeks. Shares are still down over 40% YTD and well below their 52-week high of $4.70. DRIO stock has a $4.25 price target by the lone analyst that covers the shares and assigns DRIO a rating of “Strong Buy”.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $DRIO and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: James Marion is a University of Houston student studying Business with a concentration in Finance. James has interned with several investment professionals and hopes to pursue a career as a professional stock analyst after graduation.

Shares of Stellar Biotechnologies Inc (NASDAQ:SBOT) Have Wild Ride

Stellar Biotechnologies Inc (NASDAQ:SBOT)

Stellar Biotechnologies Inc (NASDAQ:SBOT) failed, on heavy volume, to rise above the $1.38 high reached on October 13. SBOT stock jumped in the morning from an open at $1.15 but after 90 minutes sellers jumped in and pushed the shares back down to $1.22. There have been no news items coming across the wires that may have explained the early jump in price.

Stellar Biotechnologies Inc (NASDAQ:SBOT)

Port Hueneme, CA-based Stellar Biotechnologies Inc (NASDAQ:SBOT) has a market capitalization of less than $12 million and a stock float under eight million. The global biotechnology firm specializes in aquaculture, research and development, manufacture, and commercialization of keyhole limpet hemocyanin (KLH) protein. KLH is an immune-stimulating protein used for generation of antibody and cell-mediated immune responses against disease indications such as cancer and immune disorders. It provides its products under the Stellar KLH brand name.

Sales have been increasing for the past three years. In 2014, sales were posted at $400,000 and in 2016 the figure was an impressive $1.3 million. However, share dilution has been plaguing investors. In 2014, there were 7.58 million shares outstanding and that number grew to 8.83 million by 2016. Also of concern is the lack of profit – losses have been posted by Stellar Biotechnologies Inc (NASDAQ:SBOT) since 2012. For 2016 the per share loss was (-$0.57), a worse loss than the (-$0.36) shareholders experienced in 2015.

SBOT Stock

Zack’s investor Services covers SBOT stock and assigns the shares a rating of “Strong Buy”. However SBOT stock has lost over 46% for the past year, and is down over 17% for the quarter. Still, as of this writing (1 PM EST), shares are up almost 7% for the day. A casual review of a SBOT daily stock chart shows that for the past couple of months, SBOT shares have hit significant support at $1.10.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $SBOT and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.